SCHEMBL6492652

SCHEMBL6492652

C=Cc1nn(Cc2nc3cc(C(N)C(=O)OC(C)(C)C)ccc3n2CCCCOC(=O)C(C)(C)C)c2ccccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MAPT P10636 1/20 0.35
TP53 P04637 2/20 0.34
POLB P06746 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PTGER4 P35408 6/20 0.33
BRD4 O60885 1/20 0.33
RECQL P46063 1/20 0.32
RAB9A P51151 1/20 0.32
ATM Q13315 1/20 0.32
PSEN1 P49768 1/20 0.31
PSEN2 P49810 1/20 0.31
APH1B Q8WW43 1/20 0.31
NCSTN Q92542 1/20 0.31
APH1A Q96BI3 1/20 0.31
PSENEN Q9NZ42 1/20 0.31
STING1 Q86WV6 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6216586 0.85 CYP2D6 (0.39) MAPTTP53POLBL3MBTL1SMN1; SMN2
SCHEMBL6493197 0.81 TP53 (0.35) MEN1KMT2AMAPTTP53POLB
SCHEMBL6493461 0.81 SMN1; SMN2 (0.40) MEN1KMT2AMAPTTP53POLB
SCHEMBL6217861 0.81 MAPT (0.36) MAPTTP53POLBL3MBTL1SMN1; SMN2
SCHEMBL6217704 0.80 PTGER4 (0.34) MEN1KMT2AMAPTTP53POLB
SCHEMBL6220285 0.79 CYP3A4 (0.41) MEN1KMT2AMAPTTP53POLB
SCHEMBL6247154 0.75 CYP2D6 (0.41) MEN1KMT2AL3MBTL1BRD4RECQL
SCHEMBL6276414 0.73 PTGER4 (0.34) MEN1KMT2AMAPTTP53PTGER4
SCHEMBL6489815 0.70 MEN1 (0.38) MEN1KMT2APOLB
SCHEMBL6222254 0.67 TP53 (0.38) MEN1KMT2AMAPTTP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919331-B2 Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2005-07-19 US disclosed
US-20030207868-A1 Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents BRISTOL-MYERS SQUIBB COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207868-A1 Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents MAVS, ZC3HAV1, EIF2AK2 MEN1 4565/4885KMT2A 249/4885MAPT 4825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.